Company intelligence / Profile preview

Caribou Industries

Berkeley, California, United Statesmichaelfharrah.com ↗

Ownership: Private
Employees: ~125
Development stage: Other

Overview

Caribou’s two lead allogeneic CAR-T therapies, CB‑010 and CB‑011, are in Phase 1 trials targeting B-cell non-Hodgkin lymphoma and multiple myeloma. The company recently reprioritized its pipeline to focus exclusively on these oncology indications after discontinuing other programs. Clinical data readouts have been delayed to the second half of 2025 due to restructuring.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyCRISPR-based therapyAllogeneic cell therapy
Industry: Biotech

Partnerships

AbbVie Inc.The Leukemia & Lymphoma Society

Beyond the preview

Go deeper on Caribou Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caribou Industries.

Explore the full profile